Keyword: Emgality

Amgen had a head start on the CGRP race with its first-in-class approval for Aimovig, but now it's slipped under 50% total market share.

Hard on the heels of its CGRP migraine competitors, Eli Lilly’s Emgality has been looking for a leg up. Solid data in preventing migraines as a follow-up treatment could do the trick.

Eli Lilly’s CGRP drug Emgality is in a heated market share race with Amgen’s Aimovig and Teva’s Ajovy, but in Q2, it gained some steam.

Sales of Lilly’s Emgality have lagged behind rivals. And to bring payers on board, Lilly is deploying a full-court press with new patient data.

Biohaven could soon go up against large drugmakers' CGRP injectables Aimovig, Ajovy and Emgality with its oral drug rimegepant.

Cluster headache pain is so intense one patient describes banding his head against the refrigerator door to make it stop in Eli Lilly’s new educational video.

Lilly is trailing its migraine-prevention rivals in early sales results, but now the company is alone in boasting a cluster headache approval.

Facing Amgen's first-to-market advantage and Eli Lilly's marketing muscle, Teva's migraine drug Ajovy is relying on an underdog-style promo push.

Teva's decision to abandon the cluster headache market gives Eli Lilly and its CGRP med Emgality a shot at dominating the indication.

Amgen wants to exit its collaboration with Novartis on migraine prevention drug Aimovig.